ORIGINAL ARTICLE
GALACTOMANNAN ANTIGEN TEST IN RESPIRATORY SAMPLES FOR ASPERGILLOSIS DIAGNOSIS

UDK: 616-006.6-036.81:[616.992:582.282.123.4

Mirchevska G.

 

1Institute of Microbiology and Parasitology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, Republic of North Macedonia

 

 

Abstract

Introduction: Invasive aspergillosis is an important cause of mortality in patients with malignant diseases, and is an underestimated infection in critically ill patients. Early diagnosis is still challenging, therefore a rapid and more sensitive diagnostic methods could be beneficial.

Aim: the aim of the study was to evaluate the sensitivity and specificity of the galactomannan antigen test in respiratory samples, compared to conventional methods, for early diagnosis of aspergillosis.

Material and methods: Samples of 125 patients divided into 4 groups, classified according to diagnosis and EORTC/MSG criteria, were analysed at the Institute of Microbiology and Parasitology, with culture and galactomannan test in respiratory samples, during a period of two years.

Results: A total of 71 isolates of Aspergillus were confirmed in this study. Culture of respiratory samples revealed Aspergillus in the group of chronic aspergillosis (63.33%), followed by groups of cystic fibrosis (56.67%), primary immune deficiency (51.43%), and the group with prolonged ICU stay (43.33%). Sensitivity and specificity of respiratory samples’ culture were: 64.29% and 100%, 59.09% and 100%, 54.55% and 12.5%, 100% and 54.17%, in all four groups, respectively. Sensitivity and specificity of galactomannan in respiratory samples, were: 75% and 57.14%, 86.36% and 62.5%, 81.82% and 0%, 50% and 70.83%, in all 4 groups, respectively.

Conclusion: The results of this study demonstrate that positive galactomannan test in respiratory samples could be a useful diagnostic adjunct in diagnosis of aspergillosis, along with results from conventional mycological analyses, so timely antifungal treatment is administered.

 

Key words: Aspergillus, aspergillosis, galactomannan, respiratory tract

 

 

 

References:

  1. Zaragoza R, Sole-Violan J, Cusack R, et al. Invasive Pulmonary Aspergillosis: Not Only a Disease Affecting Immunosuppressed Patients. Diagnostics (Basel). 2023 Jan 26;13(3):440. doi: 10.3390/diagnostics13030440.
  2. Mirchevska G, Kotevska V, Kaftandzieva A, Kirovski I, Stojanoski Z, Trajkovska-Dokic E. Evaluation of BAL PCR for diagnosis of aspergillosis. Macedonian Journal of Anaesthesia. 2022; 6(2),11-21. UDK: 616-022.6:582.282.123.4.
  3. Janssens I, Lambrecht BN, Van Braeckel E. Aspergillus and the Lung. Semin Respir Crit Care Med. 2024 Feb;45(1):3-20. doi: 10.1055/s-0043-1777259. Epub 2024 Jan 29.
  4. Trelles M, Murillo J, Fuenmayor-González L, et al. Prevalence of invasive fungal infection in critically Ill patients: a systematic review and meta-analysis. BMC Infect Dis. 2025 Jul 5;25(1):896. doi: 10.1186/s12879-025-11264-z.
  5. Bassetti M, Azoulay E, Kullberg BJ, et al. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clin Infect Dis. 2021 Mar 12;72(Suppl 2):S121-S127. doi: 10.1093/cid/ciaa1751.
  6. Fontaine T, Latgé JP. Galactomannan Produced by Aspergillus fumigatus: An Update on the Structure, Biosynthesis and Biological Functions of an Emblematic Fungal Biomarker.  Fungi2020, 6, 283. https://doi.org/10.3390/jof6040283
  7. Zhou W, Li H, Zhang Y, et al. Diagnostic Value of Galactomannan Antigen Test in Serum and Bronchoalveolar Lavage Fluid Samples from Patients with Nonneutropenic Invasive Pulmonary Aspergillosis. J Clin Microbiol. 2017 Jul;55(7):2153-2161. doi: 10.1128/JCM.00345-17. Epub 2017 Apr 26.
  8. Patterson TF, Thompson GR III, Denning DW, et al. 2016. Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63:433–442. doi: 10.1093/cid/ciw444
  9. D’Haese J, Theunissen K, Vermeulen E, et al. 2012. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 50:1258–1263. doi: 10.1128/JCM.06423-11.
  10. Platelia Aspergillus Antigehttp: www.bio-rad.com/webroot/web/pdf/inserts/ CDG/en/62784_881082_EN.pdf
  11. Lahmer T, Neuenhahn M, Held J, et al. Comparison of 1,3-β-d-glucan with galactomannan in serum and bronchoalveolar fluid for the detection of Aspergillus species in immunosuppressed mechanical ventilated critically ill patients. J Crit Care. 2016 Dec;36:259-264. doi: 10.1016/j.jcrc.2016.06.026. Epub 2016 Jul 9.
  12. Sanguinetti M, Posteraro B, Pagano L, et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol. 2003 Aug;41(8):3922-5. doi: 10.1128/JCM.41.8.3922-3925.2003. Erratum in: J Clin Microbiol. 2005 Jul;43(7):3588.
  13. Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol. 2007 Jun;45(6):1759-65. doi: 10.1128/JCM.00077-07. Epub 2007 Apr 11.
  14. Nguyen MH, Jaber R, Leather HL, et al. Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. J Clin Microbiol. 2007 Sep;45(9):2787-92. doi: 10.1128/JCM.00716-07. Epub 2007 Jun 27.
  15. Husain S, Paterson DL, Studer SM, et al. Aspergillus galactomannan antigen in the bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in lung transplant recipients. Transplantation. 2007, May;83(10):1330-6. doi: 10.1097/01.tp.0000263992.41003.33.
  16. Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009 Dec 1;49(11):1688-93. doi: 10.1086/647935.
  17. Park SY, Lee SO, Choi SH, et al. Serum and bronchoalveolar lavage fluid galactomannan assays in patients with pulmonary aspergilloma. Clin Infect Dis. 2011 Apr 1;52(7):e149-52. doi: 10.1093/cid/cir027.
  18. Kono Y, Tsushima K, Yamaguchi K, et al. The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis. Respir Med. 2013 Jul;107(7):1094-100. doi: 10.1016/j.rmed.2013.04.007. Epub 2013 Apr 28.
  19. Delhaes L, Frealle E, Pinel C. Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: State of the art and further challenges. Med Mycol. 2010 Nov;48 Suppl 1:S77-87. doi: 10.3109/13693786.2010.514301.
  20. Baxter CG, Dunn G, Jones AM, et al. Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol. 2013 Sep;132(3):560-566.e10. doi: 10.1016/j.jaci.2013.04.007. Epub 2013 May 29.
  21. Matveev AL, Krylov VB, Emelyanova LA, et al. Novel mouse monoclonal antibodies specifically recognize Aspergillus fumigatus galactomannan. PLoS One. 2018 Mar 8;13(3):e0193938. doi: 10.1371/journal.pone.0193938.